Alloantibodies and Congenital Bleeding Disorders: New Insights in the Pathogenesis and Management

Antonio Coppola; Annarita Tagliaferri; Cristina Santoro; Massimo Franchini

doi:10.1055/s-0038-1666824

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2018; 44(06): 505-508
DOI: 10.1055/s-0038-1666824

Preface

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Alloantibodies and Congenital Bleeding Disorders: New Insights in the Pathogenesis and Management

Antonio Coppola

¹Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Italy

,

Annarita Tagliaferri

¹Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma, Italy

,

Cristina Santoro

²Hematology Unit, Department of Cellular Biotechnology and Hematology, Sapienza University of Rome, Italy

,

Massimo Franchini

³Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Berntorp E, Gretenkort-Andersson N. Prophylaxis for hemophilia in the era of extended half-Life FVIII/FIX products. Semin Thromb Hemost 2016; 42 (05) 518-525
2 Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. Semin Thromb Hemost 2016; 42 (05) 526-532
3 Oldenburg J, Mahlangu JN, Kim B. , et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
4 Nathwani AC, Reiss UM, Tuddenham EG. , et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371 (21) 1994-2004
5 Rangarajan S, Walsh L, Lester W. , et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377 (26) 2519-2530
6 Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in patients with inhibitors to factor VIII/IX. J Clin Med 2017; 6 (04) E46
7 Franchini M, Coppola A, Rocino A. , et al. Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost 2013; 39: 752-766
8 Batorova A, Morongova A, Tagariello G, Jankovicova D, Prigancova T, Horakova J. Challenges in the management of hemophilia B with inhibitor. Semin Thromb Hemost 2013; 39 (07) 767-771
9 Rocino A, Coppola A, Franchini M. , et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (04) 575-598
10 Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009; 102 (06) 1157-1164
11 Gouw SC, van den Berg HM, Oldenburg J. , et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
12 Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost 2013; 39 (07) 740-751
13 Margaglione M, Intrieri M. Genetic risk factors and inhibitor development in hemophilia: what is known and searching for the unknown. Semin Thromb Hemost 2018; 44 (06) 509-516
14 Delignat S, Rayes J, Russick J, Kaveri SV, Lacroix-Desmazes S. and The ABIRISK consortium. Inhibitor formation in congenital haemophilia A: an immunological perspective. Semin Thromb Hemost 2018; 44 (06) 517-530
15 Hassan S, Fijnvandraat K, van der Bom JG, Gouw SC. Preventing or eradicating factor VIII antibody formation in patients with hemophilia A; what can we learn from other disorders?. Semin Thromb Hemost 2018; 44 (06) 531-543
16 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (07) 772-778
17 Barg AA, Livnat T, Kenet G. Inhibitors in hemophilia - treatment challenges and novel options. Semin Thromb Hemost 2018; 44 (06) 544-550
18 Coppola A, Franchini M, Castaman G. , et al. The AICE ad hoc Working Group. Treatment regimens with bypassing agents in patients with hemophilia A and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE). Semin Thromb Hemost 2018; 44 (06) 551-560
19 Messori A. Inhibitors in hemophilia A: a pharmacoeconomic perspective. Semin Thromb Hemost 2018; 44 (06) 561-567
20 Eckhardt CL, van Velzen AS, Peters M. , et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122 (11) 1954-1962
21 Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K. Emerging issues in diagnosis, biology and inhibitor risk in mild hemophilia A. Semin Thromb Hemost 2016; 42 (05) 507-512
22 Abdi A, Linari S, Pieri L, Voorberg J, Fijnvandraat K, Castaman G. Inhibitors in non-severe hemophilia A: what is known and searching for the unknown. Semin Thromb Hemost 2018; 44 (06) 568-577
23 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (03) 305-315
24 Franchini M, Santoro C, Coppola A. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review. Thromb Haemost 2016; 116 (01) 201-203
25 Santoro C, Quintavalle G, Castaman G. , et al. Inhibitors in hemophilia B. Semin Thromb Hemost 2018; 44 (06) 578-589
26 Franchini M, Mannucci PM. Alloantibodies in von Willebrand disease. Semin Thromb Hemost 2018; 44 (06) 590-594
27 Franchini M, Marano G, Mengoli C. , et al. Inhibitors in patients with congenital bleeding disorders other than hemophilia. Semin Thromb Hemost 2018; 44 (06) 595-603
28 Poon M-C, d'Oiron R. Alloimmunization in in congenital deficiencies of platelet surface glycoproteins: focus on Glanzmann thrombasthenia and Bernard-Soulier syndrome. Semin Thromb Hemost 2018; 44 (06) 604-614